{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T01:04:04Z","timestamp":1777511044729,"version":"3.51.4"},"reference-count":64,"publisher":"Edizioni Minerva Medica","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["G Ital Dermatol Venereol"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.23736\/s0392-0488.20.06640-7","type":"journal-article","created":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T14:48:35Z","timestamp":1602600515000},"source":"Crossref","is-referenced-by-count":10,"title":["Apremilast and its role in psoriatic arthritis"],"prefix":"10.23736","volume":"155","author":[{"given":"Vijay K.","family":"Sandhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lihi","family":"Eder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jensen","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"17149","reference":[{"key":"10.23736\/S0392-0488.20.06640-7_ref001","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.032482"},{"key":"10.23736\/S0392-0488.20.06640-7_ref002","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.07.023"},{"key":"10.23736\/S0392-0488.20.06640-7_ref003","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker365"},{"key":"10.23736\/S0392-0488.20.06640-7_ref004","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.150995"},{"key":"10.23736\/S0392-0488.20.06640-7_ref005","unstructured":"U.S. Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs; 2020 [Internet]. Available from: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&amp;ApplNo=206088 [cited 2020, Jun 17]."},{"key":"10.23736\/S0392-0488.20.06640-7_ref006","unstructured":"European Medicines Agency. Otezla; 2020 [Internet]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/otezla [cited 2020, Jun 17]."},{"key":"10.23736\/S0392-0488.20.06640-7_ref007","unstructured":"European Medicines Agency. Otezla, opinion; 2020 [Internet]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/summaries-opinion\/otezla [cited 2020, Jun 17]."},{"key":"10.23736\/S0392-0488.20.06640-7_ref008","unstructured":"Celgene Corp. OTEZLA\u00ae apremilast [prescribing information]; 2020 [Internet]. Available from: https:\/\/www.pi.amgen.com\/~\/media\/amgen\/repositorysites\/pi-amgen-com\/otezla\/otezla_pi_english.ashx [cited 2020, Jun 17]."},{"key":"10.23736\/S0392-0488.20.06640-7_ref009","doi-asserted-by":"publisher","DOI":"10.1021\/jm900210d"},{"key":"10.23736\/S0392-0488.20.06640-7_ref010","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-015-0771-6"},{"key":"10.23736\/S0392-0488.20.06640-7_ref011","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.R200029200"},{"key":"10.23736\/S0392-0488.20.06640-7_ref012","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2008-0091TR"},{"key":"10.23736\/S0392-0488.20.06640-7_ref013","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0503363102"},{"key":"10.23736\/S0392-0488.20.06640-7_ref014","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0911684106"},{"key":"10.23736\/S0392-0488.20.06640-7_ref015","doi-asserted-by":"publisher","DOI":"10.1042\/bj3470571"},{"key":"10.23736\/S0392-0488.20.06640-7_ref016","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.34.20828"},{"key":"10.23736\/S0392-0488.20.06640-7_ref017","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2014.05.014"},{"key":"10.23736\/S0392-0488.20.06640-7_ref018","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.biochem.76.060305.150444"},{"key":"10.23736\/S0392-0488.20.06640-7_ref019","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00030.2010"},{"key":"10.23736\/S0392-0488.20.06640-7_ref020","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0705770"},{"key":"10.23736\/S0392-0488.20.06640-7_ref021","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevImmunol.v26.i5.40"},{"key":"10.23736\/S0392-0488.20.06640-7_ref022","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6446(05)03622-6"},{"key":"10.23736\/S0392-0488.20.06640-7_ref023","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X10381432"},{"key":"10.23736\/S0392-0488.20.06640-7_ref024","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0704480"},{"key":"10.23736\/S0392-0488.20.06640-7_ref025","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2004.01.003"},{"key":"10.23736\/S0392-0488.20.06640-7_ref026","doi-asserted-by":"publisher","DOI":"10.2174\/0929867324666170530093902"},{"key":"10.23736\/S0392-0488.20.06640-7_ref027","unstructured":"Capone L, Rogovitz A, Gandhi A, Schafer P. Anti-inflammatory activity of apremilast against T cells, chondrocytes, and rheumatoid arthritis synovial fibroblasts in vitro [abstract 1844]; 2011 [Internet]. Available from: https:\/\/acr.confex.com\/acr\/2011\/webprogram\/Paper23923.html [cited 2020, Jun 17]."},{"key":"10.23736\/S0392-0488.20.06640-7_ref028","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2009.00559.x"},{"key":"10.23736\/S0392-0488.20.06640-7_ref029","doi-asserted-by":"publisher","DOI":"10.1186\/ar3041"},{"key":"10.23736\/S0392-0488.20.06640-7_ref030","doi-asserted-by":"publisher","DOI":"10.1002\/art.34627"},{"key":"10.23736\/S0392-0488.20.06640-7_ref031","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.121200"},{"key":"10.23736\/S0392-0488.20.06640-7_ref032","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-205056"},{"key":"10.23736\/S0392-0488.20.06640-7_ref033","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.151376"},{"key":"10.23736\/S0392-0488.20.06640-7_ref034","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207963"},{"key":"10.23736\/S0392-0488.20.06640-7_ref035","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key032"},{"key":"10.23736\/S0392-0488.20.06640-7_ref036","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1901-3"},{"key":"10.23736\/S0392-0488.20.06640-7_ref037","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211568"},{"key":"10.23736\/S0392-0488.20.06640-7_ref038","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000669"},{"key":"10.23736\/S0392-0488.20.06640-7_ref039","first-page":"S151","article-title":"Laboratory abnormalities in patients with psoriatic arthritis receiving apremilast, an oral phosphodiesterase 4 inhibitor: pooled safety analysis of three phase 3, randomized, controlled trials","volume":"65","author":"Mease PJ","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.23736\/S0392-0488.20.06640-7_ref040","first-page":"AB162","article-title":"Low serious infection rates in patients with psoriasis and psoriatic arthritis treated with apremilast for 156 weeks and beyond: pooled analysis of the phase 3 ESTEEM 1 and 2 and PALACE 1-3 trials","volume":"76","author":"Pariser DM","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.23736\/S0392-0488.20.06640-7_ref041","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchemneu.2010.03.004"},{"key":"10.23736\/S0392-0488.20.06640-7_ref042","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(98)00190-7"},{"key":"10.23736\/S0392-0488.20.06640-7_ref043","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12839"},{"key":"10.23736\/S0392-0488.20.06640-7_ref044","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M600519-JLR200"},{"key":"10.23736\/S0392-0488.20.06640-7_ref045","doi-asserted-by":"publisher","DOI":"10.1210\/en.2009-0108"},{"key":"10.23736\/S0392-0488.20.06640-7_ref046","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.2001.6259"},{"key":"10.23736\/S0392-0488.20.06640-7_ref047","first-page":"S698","article-title":"Change in weight from baseline with apremilast, an oral phosphodiesterase 4 inhibitor: pooled results from 3 phase 3, randomized, controlled trials","volume":"66","author":"Mease PJ","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.23736\/S0392-0488.20.06640-7_ref048","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.01.052"},{"key":"10.23736\/S0392-0488.20.06640-7_ref049","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex454"},{"key":"10.23736\/S0392-0488.20.06640-7_ref050","first-page":"1590","article-title":"Real-world effectiveness and safety of apremilast in german patients with psoriatic arthritis: analysis of an ongoing multicentre, prospective, non-interventional study","volume":"77","author":"Wollenhaupt K","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.23736\/S0392-0488.20.06640-7_ref051","first-page":"13","article-title":"Real-world experience with apremilast in an Australian cohort of people with psoriatic arthritis: prospective follow-up of participants in the australian rheumatology association database (ARAD)","volume":"48","author":"Fletcher A","year":"2018","journal-title":"Intern Med J"},{"key":"10.23736\/S0392-0488.20.06640-7_ref052","doi-asserted-by":"crossref","first-page":"134","DOI":"10.33590\/emjrheumatol\/10314411","article-title":"Real world experience of apremilast in treating psoriatic arthritis patients with multiple comorbidities","volume":"6","author":"Chan A","year":"2019","journal-title":"EMJ Rheumatol."},{"key":"10.23736\/S0392-0488.20.06640-7_ref053","unstructured":"A Study to evaluate the impact of apremilast (CC-10004) on MRI outcomes in subjects with psoriatic arthritis (MOSAIC); 2020 [Internet]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03783026 [cited 2020, Jun 17]."},{"key":"10.23736\/S0392-0488.20.06640-7_ref054","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-019-04674-3"},{"key":"10.23736\/S0392-0488.20.06640-7_ref055","first-page":"A142","article-title":"Safety profile of apremilast in psoriasis and psoriatic arthritis","volume":"26","author":"Acosta M","year":"2019","journal-title":"Eur J Hosp Pharm Sci Pract"},{"key":"10.23736\/S0392-0488.20.06640-7_ref056","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.109"},{"key":"10.23736\/S0392-0488.20.06640-7_ref057","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.02.014"},{"key":"10.23736\/S0392-0488.20.06640-7_ref058","doi-asserted-by":"publisher","DOI":"10.2174\/1573397115666181130094455"},{"key":"10.23736\/S0392-0488.20.06640-7_ref059","doi-asserted-by":"publisher","DOI":"10.5152\/eurjrheum.2018.17188"},{"key":"10.23736\/S0392-0488.20.06640-7_ref060","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2016.1140026"},{"key":"10.23736\/S0392-0488.20.06640-7_ref061","doi-asserted-by":"publisher","DOI":"10.1186\/s41927-018-0011-1"},{"key":"10.23736\/S0392-0488.20.06640-7_ref062","unstructured":"Efficacy, safety, and tolerability study of apremilast to treat early oligoarticular psoriatic arthritis (FOREMOST); 2020 [Internet]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03747939 [cited 2020, Jun 17]."},{"key":"10.23736\/S0392-0488.20.06640-7_ref063","first-page":"2046","article-title":"A phase IV, multicenter, single-arm, openlabel study to evaluate the impact of apremilast on hand and whole-body mri outcomes in patients with psoriatic arthritis (MOSAIC): Rationale, design and methods","volume":"78","author":"Ostergaard M","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.23736\/S0392-0488.20.06640-7_ref064","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208337"}],"container-title":["Giornale Italiano di Dermatologia e Venereologia"],"original-title":[],"link":[{"URL":"https:\/\/www.minervamedica.it\/pdf.php?cod=R23Y2020N04A0386","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T17:18:07Z","timestamp":1696871887000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.minervamedica.it\/index2.php?show=R23Y2020N04A0386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":64,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.23736\/s0392-0488.20.06640-7","relation":{},"ISSN":["0392-0488","1827-1820"],"issn-type":[{"value":"0392-0488","type":"print"},{"value":"1827-1820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10]]}}}